HPLC DETERMINATION OF VITEXIN-4″- O -GLUCOSIDE IN MOUSE PLASMA AND TISSUES AFTER ORAL AND INTRAVENOUS ADMINISTRATION

Journal of Pharmacy and Pharmacology

et al. 2013

Self Cite

Section: Resultsmentioning

confidence: 79%

Section: Introductionmentioning

confidence: 99%

Hepatic and gastrointestinal first-pass effects of vitexin-4″-O-glucoside in rats

Chen

Journal of Pharmacy and Pharmacology

et al. 2013

Self Cite

“…The highest concentration of VG was found in stomach, followed by intestine and liver at 0.5 h after oral administration (Fig. B), and the concentration of VG in stomach and intestine gradually decreased, meaning that VG was absorbed in the stomach then transferred to others organs (Chen et al ., ). Thehigher concentrations of VG in intestine could also be attributed to its emptying partly from stomach to the intestine or the enterohepatic circulation (Cai et al ., ).…”

Section: Resultsmentioning

confidence: 97%

Tissue distribution comparison between healthy and fatty liver rats after oral administration of hawthorn leaf extract

Yin

Qu²,

Biomedical Chromatography

et al. 2013

Self Cite

Hawthorn leaves, a well-known traditional Chinese medicine, have been widely used for treating cardiovascular and fatty liver diseases. The present study aimed to investigate the therapeutic basis treating fatty liver disease by comparing the tissue distribution of six compounds of hawthorn leaf extract (HLE) in fatty liver rats and healthy rats after oral administration at first day, half month and one month, separately. Therefore, a sensitive and specific HPLC method with internal standard was developed and validated to determine chlorogenic acid, vitexin-4''-O-glucoside, vitexin-2''-O-rhamnoside, vitexin, rutin and hyperoside in the tissues including heart, liver, spleen, kidney, stomach and intestine. The results indicated that the six compounds in HLE presented some bioactivity in treating rat fatty liver as the concentrations of the six compounds varied significantly in inter- and intragroup comparisons (healthy and/or fatty liver group).

“…The results showed that the elimination of VOG after the two routes was fairly low, which meant that VOG was metabolized as other forms. The elimination after oral dosing was almost 4.3-fold that after intravenous dosing, according to the results of a study on pharmacokinetics and tissue distribution of VOG in mice after oral and intravenous administration (Chen et al, 2013). The plasma concentration of VOG after intravenous dosing was significantly higher than that after oral dosing.…”

Section: Excretion Studiesmentioning

confidence: 97%

“…Vitexin-4 00 -O-glucoside (VOG) as a unique flavone presents a strongly antioxidant effect (Ying et al, 2008) and also can protect the heart against anoxia/reoxygenation injury . In recent years, many studies of VOG in vivo (Ma et al, 2007;Ying et al, 2012;Chen et al, 2013) have also been reported. However, there is little research on the comparative excretion of pure VOG isolated from leaves of Crataegus pinnatifida Bge.…”

Section: Introductionmentioning

confidence: 99%

Comparative study on the excretion of vitexin‐4′′‐O‐glucoside in mice after oral and intravenous administration by using HPLC

Cai

Chen

Biomedical Chromatography

et al. 2013

Self Cite

The aim of the present study was to characterize the excretion of pure vitexin-4"-O-glucoside (VOG) in mice following oral and intravenous administration at a dose of 30 mg/kg. A sensitive and specific HPLC method with hespridin as internal standard, a Diamonsil C18 column protected with a KR C18 guard column and a mixture consisting of methanol-acetonitrile-tetrahydrofuran-0.1% glacial acetic acid (6:2:18:74, v/v/v/v) as mobile phase was developed and validated for quantitative analysis in biological samples. VOG could be excreted as prototype in excreta including urine and feces after both routes of administration, and the cumulative excretion of VOG was 24.31 ± 11.10% (17.97 ± 5.59% in urinary excretion; 6.34 ± 5.51% in fecal excretion) following oral dosing and 5.66 ± 3.94% (4.78 ± 3.13% in urinary excretion; 0.88 ± 0.81% in fecal excretion) following intravenous dosing. The results showed that the elimination of VOG after the two routes was fairly low, which meant that VOG was metabolized as other forms and the elimination after oral dosing was almost 4.3-fold that after intravenous dosing. For both routes of administration, VOG excreted as prototype in urine was much more than that in feces, nearly 2.83-fold for oral administration and 5.43-fold for intravenous administration, which should be attributed to enterohepatic circulation. Taken together, renal excretion was the dominant path of elimination of VOG for oral and intravenous administration in mice and biliary excretion contributed less.